Y Wang1, P T Katzmarzyk1, R Horswell1, W Zhao1, J Johnson2, G Hu1. 1. Pennington Biomedical Research Center, Baton Rouge, LA, USA. 2. Health Care Service Division, Louisiana State University Health Science Center, Baton Rouge, LA, USA.
Abstract
AIMS: To investigate the risk prediction and the risk stratification performances of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and the Modification of Diet in Renal Disease (MDRD) equation for estimated glomerular filtration rate (eGFRCKD - EPI vs. eGFRMDRD ) on heart failure in patients with Type 2 diabetes. METHODS: The study cohort included 12 258 White and 16 886 African American low-income patients with Type 2 diabetes who were 30-90 years old at baseline. Heart failure risk according to different eGFRCKD - EPI and eGFRMDRD categories was prospectively assessed. RESULTS: During a mean follow-up of 6.5 years, 5043 incident heart failure cases were identified. Multivariable-adjusted hazard ratios (HRs) of heart failure associated with the eGFRCKD - EPI categories [≥ 90 (reference group), 75-89, 60-74, 30-59 and < 30 ml/min/1.73 m(2) ] were 1.00, 1.11, 1.31, 1.75 and 2.93 (Ptrend < 0.001) for African American patients, and 1.00, 1.11, 1.08, 1.59 and 2.92 (Ptrend < 0.001) for White patients, respectively. The model with eGFRCKD - EPI and the other risk factors had significantly higher Harrell's C than the model with eGFRMDRD and other risk factors. Patients reclassified downward from eGFRMDRD 60-74 to eGFRCKD - EPI 30-59 and from eGFRMDRD 30-59 to eGFRCKD - EPI < 30 ml/min/1.73 m(2) showed higher heart failure risk than those who were not reclassified. CONCLUSIONS: Impaired kidney function (i.e. GFR < 60 ml/min/1.73 m(2) ), and even mildly decreased GFR (60-74 ml/min/1.73 m(2) ) estimated by both equations is associated with an increased risk of heart failure. Compared with GFR estimated using the MDRD equation, GFR estimated using the CKD-EPI equation added more predictive power to the model with the other risk factors. Also, eGFRCKD - EPI provided more accurate heart failure risk stratification than eGFRMDRD .
AIMS: To investigate the risk prediction and the risk stratification performances of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and the Modification of Diet in Renal Disease (MDRD) equation for estimated glomerular filtration rate (eGFRCKD - EPI vs. eGFRMDRD ) on heart failure in patients with Type 2 diabetes. METHODS: The study cohort included 12 258 White and 16 886 African American low-income patients with Type 2 diabetes who were 30-90 years old at baseline. Heart failure risk according to different eGFRCKD - EPI and eGFRMDRD categories was prospectively assessed. RESULTS: During a mean follow-up of 6.5 years, 5043 incident heart failure cases were identified. Multivariable-adjusted hazard ratios (HRs) of heart failure associated with the eGFRCKD - EPI categories [≥ 90 (reference group), 75-89, 60-74, 30-59 and < 30 ml/min/1.73 m(2) ] were 1.00, 1.11, 1.31, 1.75 and 2.93 (Ptrend < 0.001) for African American patients, and 1.00, 1.11, 1.08, 1.59 and 2.92 (Ptrend < 0.001) for Whitepatients, respectively. The model with eGFRCKD - EPI and the other risk factors had significantly higher Harrell's C than the model with eGFRMDRD and other risk factors. Patients reclassified downward from eGFRMDRD 60-74 to eGFRCKD - EPI 30-59 and from eGFRMDRD 30-59 to eGFRCKD - EPI < 30 ml/min/1.73 m(2) showed higher heart failure risk than those who were not reclassified. CONCLUSIONS:Impaired kidney function (i.e. GFR < 60 ml/min/1.73 m(2) ), and even mildly decreased GFR (60-74 ml/min/1.73 m(2) ) estimated by both equations is associated with an increased risk of heart failure. Compared with GFR estimated using the MDRD equation, GFR estimated using the CKD-EPI equation added more predictive power to the model with the other risk factors. Also, eGFRCKD - EPI provided more accurate heart failure risk stratification than eGFRMDRD .
Authors: Yujie Wang; Liwei Chen; Ronald Horswell; Ke Xiao; Jay Besse; Jolene Johnson; Donna H Ryan; Gang Hu Journal: J Womens Health (Larchmt) Date: 2012-03-02 Impact factor: 2.681
Authors: Wei Li; Yujie Wang; Liwei Chen; Ronald Horswell; Ke Xiao; Jay Besse; Jolene Johnson; Donna H Ryan; Gang Hu Journal: Diabetes Res Clin Pract Date: 2011-09-01 Impact factor: 5.602
Authors: Yujie Wang; Peter T Katzmarzyk; Ronald Horswell; Wei Li; Ke Xiao; Jay Besse; Wenting Xie; Jolene Johnson; Steven Heymsfield; Donna H Ryan; Gang Hu Journal: J Clin Endocrinol Metab Date: 2012-09-13 Impact factor: 5.958
Authors: Yujie Wang; Liwei Chen; Ke Xiao; Ronald Horswell; Jay Besse; Jolene Johnson; Donna H Ryan; Gang Hu Journal: J Womens Health (Larchmt) Date: 2011-10-24 Impact factor: 2.681
Authors: Wenhui Zhao; Peter T Katzmarzyk; Ronald Horswell; Yujie Wang; Jolene Johnson; William T Cefalu; Donna H Ryan; Gang Hu Journal: J Clin Endocrinol Metab Date: 2013-05-28 Impact factor: 5.958
Authors: Caroline S Fox; Kunihiro Matsushita; Mark Woodward; Henk J G Bilo; John Chalmers; Hiddo J Lambers Heerspink; Brian J Lee; Robert M Perkins; Peter Rossing; Toshimi Sairenchi; Marcello Tonelli; Joseph A Vassalotti; Kazumasa Yamagishi; Josef Coresh; Paul E de Jong; Chi-Pang Wen; Robert G Nelson Journal: Lancet Date: 2012-09-24 Impact factor: 79.321
Authors: Gang Hu; Ronald Horswell; Yujie Wang; Wei Li; Jay Besse; Ke Xiao; Honglei Chen; Jeffrey N Keller; Steven B Heymsfield; Donna H Ryan; Peter T Katzmarzyk Journal: PLoS One Date: 2012-09-05 Impact factor: 3.240
Authors: Wenhui Zhao; Peter T Katzmarzyk; Ronald Horswell; Yujie Wang; Wei Li; Jolene Johnson; Steven B Heymsfield; William T Cefalu; Donna H Ryan; Gang Hu Journal: Diabetes Care Date: 2013-05-20 Impact factor: 19.112
Authors: Yun Shen; Lizheng Shi; Elizabeth Nauman; Peter T Katzmarzyk; Eboni G Price-Haywood; Alessandra N Bazzano; Somesh Nigam; Gang Hu Journal: Stroke Date: 2019-02 Impact factor: 7.914
Authors: Yun Shen; Lizheng Shi; Elizabeth Nauman; Peter T Katzmarzyk; Eboni G Price-Haywood; Ping Yin; Alessandra N Bazzano; Somesh Nigam; Gang Hu Journal: J Diabetes Date: 2018-11-13 Impact factor: 4.006
Authors: Marcelo Arruda Nakazone; Maurício Nassau Machado; Ana Paula Otaviano; Ana Maria Silveira Rodrigues; Augusto Cardinalli-Neto; Reinaldo Bulgarelli Bestetti Journal: Cardiol Res Pract Date: 2020-07-06 Impact factor: 1.866
Authors: Yun Shen; Lizheng Shi; Elizabeth Nauman; Peter T Katzmarzyk; Eboni G Price-Haywood; Alessandra N Bazzano; Somesh Nigam; Gang Hu Journal: J Clin Endocrinol Metab Date: 2020-01-01 Impact factor: 5.958
Authors: Yun Shen; Jian Zhou; Lizheng Shi; Elizabeth Nauman; Peter T Katzmarzyk; Eboni G Price-Haywood; Ronald Horswell; Alessandra N Bazzano; Somesh Nigam; Gang Hu Journal: Diabetes Obes Metab Date: 2020-10-07 Impact factor: 6.577
Authors: Yuxin Fan; Li Ding; Yalan Zhang; Hua Shu; Qing He; Jingqiu Cui; Gang Hu; Ming Liu Journal: Front Endocrinol (Lausanne) Date: 2022-03-04 Impact factor: 5.555